New Jersey § 24:6e-4
Full text of New Jersey New Jersey Statutes § 24:6e-4, with citation guidance and answers to common questions.
§ 24:6e-4.
As used in this act unless the context clearly indicates otherwise: a. “ Drug product ” means a dosage form containing one or more active therapeutic ingredients along
with other substances included during the manufacturing process. The term “drug product” does not include “biological product” as defined in section
1 of P.L.2015, c. 130 ( C.24:6K-1 ) . b. “ Brand name ” means the proprietary name assigned to a drug by the manufacturer thereof. c. “ Established name ” with respect to a drug or ingredient thereof, means (1) the applicable official
name designated pursuant to the Federal Food, Drug and Cosmetic Act ( Title 21, U.S.C. s.301 et seq. ), or (2) if there is no such official name and such drug or ingredient is recognized
in an official compendium, then the official title thereof in such compendium, except
that where a drug or ingredient is recognized in the United States Pharmacopoeia and
in the Homeopathic Pharmacopoeia under different official titles, the official title
used in the United States Pharmacopoeia shall apply unless it is labeled and offered
for sale as a homeopathic drug, in which case the official title used in the Homeopathic
Pharmacopoeia shall apply, or (3) if neither (1) nor (2) is applicable, then the common
or usual name, if any, of such drug or ingredient. d. “ Prescription ” means an order for drugs or combinations or mixtures thereof, written or signed
by a duly licensed physician, dentist, veterinarian, or other medical practitioner
licensed to write prescriptions intended for the treatment or prevention of disease
in man or animals, and includes orders for drugs or medicines or combinations or mixtures
thereof transmitted to pharmacists through word of mouth, telephone, telegraph, or
other means of communication by a duly licensed physician, dentist, veterinarian,
or other medical practitioner licensed to write prescriptions intended for the treatment
or prevention of disease in man or animals. e. “ Department ” means the Department of Health. f. “ Chemical equivalents ” means those drug products that contain the same amounts of the same therapeutically
active ingredients in the same dosage forms and that meet present compendial standards. g. “ Reference drug product ” means the product which is adopted by the department as the standard for other chemically
equivalent drugs in terms of testing for the therapeutic equivalence. In all cases, the reference drug product shall be a currently marketed drug which
is the subject of a full (not abbreviated) new drug application approved by the Federal
Food and Drug Administration. h. “ Therapeutic equivalents ” means chemical equivalents which, when administered to the same individuals in the
same dosage regimen, will provide essentially the same efficacy or toxicity as their
respective reference drug products. i. “ Bioavailability ” means the extent and rate of absorption from a dosage form as reflected by the time-concentration
curve of the administered drug in the systemic circulation. j. “ Bioequivalents ” means chemical equivalents which, when administered to the same individuals in the
same dosage regimen, will result in comparable bioavailability. k. “ Pharmaceutical equivalents ” means those drug products that contain the same amounts of the same therapeutically
active ingredients in the same dosage form and that meet established standards. l . “ Interchangeable drug products ” means pharmaceutical equivalents or bioequivalents that are determined to be therapeutic
equivalents by the department. m. “ Present compendial standards ” means the official standards for drug excipients and drug products listed in the
latest revision of the United States Pharmacopoeia (USP) and the National Formulary
(NF). n. “ Dosage form ” means the physical formulation or medium in which the product is intended, manufactured
and made available for use, including, but not limited to: tablets, capsules, oral
solutions, aerosols, inhalers, gels, lotions, creams, ointments, transdermals and
suppositories, and the particular form of the above which utilizes a specific technology
or mechanism to control, enhance, or direct the release, targeting, systemic absorption,
or other delivery of a dosage regimen in the body.
Frequently Asked Questions About New Jersey § 24:6e-4
What does New Jersey Statutes § 24:6e-4 cover?
Section 24:6e-4 is part of the New Jersey Statutes, the codified statutory law of New Jersey. It sets out the legal rule or procedure described in the text above. Statutes are amended regularly, so always verify against the official source.
How do I cite New Jersey § 24:6e-4?
A common citation format is "New Jersey Statutes § 24:6e-4" (New Jersey). Legal writing may require the code abbreviation, section number, and year or edition. Match the style required by your court, professor, or publisher.
Is this the official text of New Jersey law?
No. This page is for research and education and may not include the most recent amendments. For official current law, check the New Jersey official source linked on this page or consult a licensed New Jersey attorney.
How does New Jersey § 24:6e-4 apply to my situation?
Statutes are interpreted in context, and application depends on your specific facts. Only a licensed attorney in New Jersey can advise on how this section applies to you. Contact your state or local bar association for a referral.
Sources & Verification
Not legal advice. Verify against the official source and consult a licensed attorney in New Jersey.